Background
==========

The prevalence of type 2 diabetes mellitus (T2DM) in Korean population has dramatically increased over last decades. Although Asian populations traditionally had a low percentage of T2DM patients, it has increased drastically in recent decades. This is largely due to the fact that Asian countries are adopting western lifestyle and diets. However, a recent discovery of diabetes-susceptible loci on human chromosomes suggest that genetic factors may also play a role in the disease development \[[@B1]\].

Gestational diabetes mellitus (GDM) is a condition in which pregnant women exhibit glucose intolerance in various degrees \[[@B2]\], affecting approximately 2-14% of pregnancies \[[@B1],[@B3],[@B4]\]. Women with GDM show similar physiological and genetic characteristics found in diabetes outside of pregnancy, and not surprisingly, women with GDM possess higher risk for developing T2DM when they are not pregnant. Therefore, studying GDM is a good way to study early pathogenesis of diabetes and possibly develop treatment or remedy for the disease \[[@B5]\]. However, while genetic studies on T2DM are very robust \[[@B6],[@B7]\], there are relatively fewer genetic studies for GDM.

Advance of technology in the genetics field has provided us with a number of useful tools to study human genome. Among them, genome wide association studies (GWAS) are a powerful and useful way to detect genes associated with various diseases, including diabetes. Recently, a couple of studies have revealed that the genetic variants in *melatonin receptor 1 B*(*MTNR1B*) gene are associated with T2DM and fasting glucose levels \[[@B8],[@B9]\]. *MTNR1B*gene encodes MT2 protein which, along with MT1 protein encoded by *MTNR1A*, is one of two high-affinity forms of melatonin receptor. This gene product is also an integral membrane protein forming a G-protein coupled 7-transmembrane receptor. Melatonin, also known chemically as N-acetyl-5-methoxytryptamine, is a primary neurohormone secreted by pineal gland. It is mostly found in retina and brain, and its main function is thought to be the regulation of circadian rhythm by translating photoperiodic information from the eyes to the brain. There have been some studies suggesting that insulin level is regulated by circadian clock. Furthermore, T2DM patients have exhibited impaired melatonin secretion and circadian rhythm \[[@B10]\].

To date, several studies have shown the association between *MTNR1B*and T2DM \[[@B6],[@B11]\], but there has yet to be a study which looked into the association between *MTNR1B*and GDM. Since GDM shares many clinical features with T2DM, there is a high possibility that *MTNR1B*is associated with predisposition of GDM. Therefore, we conducted an association study between two polymorphisms of *MTNR1B*, which were previously associated with T2DM, using 928 GDM patients and 990 controls. In addition, we also examined the possible association between the two SNPs of *MTNR1B*and clinical phenotypes related to GDM, such as insulin sensitivity and beta-cell function.

Methods
=======

Subjects
--------

All 1,918 subjects included in this study were of Korean ethnic origin and recruited from Cheil General Hospital in Seoul, Korea, from 2003 to 2009. The clinical profiles of the patients are summarized in Table [1](#T1){ref-type="table"}. All pregnant women who had not been previously diagnosed with T2DM were screened for GDM using a universal two-step GDM screening program at 24-28 week during gestation (GDM patients mean gestational week = 26.03 ± 2.69, NGT (Normal glucose tolerance) patients mean gestational week = 26.12 ± 1.69, Table [1](#T1){ref-type="table"}). The first step was a 50-g glucose challenge test; if the result was positive (plasma glucose levels over 7.8 mmol/liter) after 1 hour, it was followed by conducting a 100-g, 3-hour oral glucose tolerance test (OGTT) after overnight fast according to criteria outlined by Carpenter and Coustan \[[@B12]\]. The threshold glucose values were as follows: fasting, at least 5.3 mmol/liter, 1 hour, at least 10.0 mmol/liter, 2 hours, at least 8.6 mmol/liter, and 3 hours, at least 7.8 mmol/liter. Plasma glucose concentrations were measured by the glucose oxidase method using a YSI 2300 STAT (YSI; Yellow Springs, Ohio). Insulin concentrations were measured using a human-specific radioimmunoassay kit (Linco Research, St. Charles, MO). If two or more of the glucose values were met or exceeded the above thresholds, GDM was diagnosed. A total of 928 GDM women were included in this study. 299 who were negative for 50-gr glucose challenge test and 691 who were pregnant and identified as normal glucose tolerant after undergoing the 100 gr. Glucose challenge test. The homeostasis model assessment (HOMA) index was used to calculate beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) in various populations \[[@B13],[@B14]\]. Our study conforms to the Helsinki declaration and also to the Korean legislation. The institutional review board of Cheil General Hospital approved the study, and all subjects in the study provided informed consent.

###### 

Clinical profiles of subjects

  Profiles                                                     GDM               Controls          *P*value
  ------------------------------------------------------------ ----------------- ----------------- ----------
  Number of subjects                                           928               990               
  Age(yr)                                                      33.17 (22-52)     32.24 (23-44)     \<0.0001
  Mean gestation week (wk)                                     26.03 ± 2.69      26.12 ± 1.69      0.37
  BMI(kg/m2)                                                   23.32 ± 4.01      21.40 ± 2.93      \<0.0001
  AUC-G (Area under glucose curve)                             482.46 ± 57.04    358.72 ± 39.99    \<0.0001
  HOMA-B (Homeostatic model assessment, β-cell function)       208.06 ± 112.75   268.30 ± 179.88   \<0.0001
  HOMA-IR (Homeostatic model assessment, insulin resistance)   3.07 ± 1.76       2.14 ± 1.02       \<0.0001
  Fasting plasma insulin (pmol/liter)                          13.51 ± 6.62      10.82 ± 4.72      \<0.0001
  Fasting plasma glucose (pmol/liter)                          89.95 ± 13.72     79.31 ± 6.11      \<0.0001

Data are presented as means ± standard deviation except age. Data are presented as SD.

SNP genotyping
--------------

Two polymorphisms of *MTNR1B*previously reported in a T2DM association study were selected and were genotyped using a TaqMan \[[@B15]\] assay in the Korean population. Genotyping quality control was performed in 10% of the samples by duplicate checking (rate of concordance in duplicates \> 99%). The genotyping call success rates were 98.07% and 97.71% for *rs1387153*and *rs10830963*, respectively. The probes used were C_1932612_10 for rs1387153 and C_3256858_10 for rs10830963.

Statistical analyses
--------------------

The allele distributions of polymorphisms among GDM patients and normal subjects were evaluated by *x*^2^models calculating odds ratios (ORs), 95% confidence intervals (CIs), and corresponding *P*values. We used SAS version 9.1 (SAS Inc., Cary, NC) for the calculation. Multiple regressions were used for association analyses of GDM-related phenotypes adjusting for age and body mass index (BMI) as covariates, also using SAS version 9.1. Linkage disequilibrium between the two SNPs were calculated by the Haploview v4.1 software downloaded from the Broad Institute <http://www.broadinstitute.org/mpg/haploview>\[[@B16]\]. Statistical power of association was calculated by using Power for Genetic Association software \[[@B17]\]. For the calculation, disease prevalence of GDM was estimated to be 3%, based on previous researches \[[@B18]\], with risk allele frequencies of 0.503 and 0.521 for *rs1387153*and *rs10830963*respectively, and odd ratios of 1.3 and 1.35, also for respective polymorphisms. With these parameters, it was calculated that our sample of 928 cases and 990 controls would have over 90% statistical power with a type I error rate of 0.05. In order to correct the data for multiple testing, Bonferroni correction was applied. Also, we used PHASE software for haplotype inference \[[@B19]\], and inferred haplotypes were analyzed using SAS version 9.1 for the logistic analyses.

Also, we used PHASE software to estimate individual haplotypes and their frequencies, which uses a Bayesian approach. Individuals with phase probabilities less than 97% were excluded in analysis. To analyze the associations of haplotypes, we used Haplo.stats <http://mayoresearch.mayo.edu/schaid_lab/software.cfm>, which provides several haplotype-specific tests for association, as well as adjustment for non-genetic covariates and computation of simulation *P*-values. We also conducted conditional analyses with PLINK software <http://pngu.mgh.harvard.edu/~purcell/plink/>.

Results
=======

Nine hundred and twenty eight GDM patients were recruited for the present study, and we also recruited 990 pregnant women with normal glucose tolerance as controls. The clinical profiles of the subjects are summarized in Table [1](#T1){ref-type="table"}, with characteristics related with T2DM such as the area under glucose curve (AUC-G), fasting plasma insulin (FPI), and fasting plasma glucose (FPG). We also obtained homeostatic model assessment data for both groups in beta-cell function and insulin resistance (HOMA-B and HOMA-IR, respectively). Most of the phenotypes investigated for the subjects showed significant difference between the GDM patients group and the control group, (Table [1](#T1){ref-type="table"}, P value \< 0.0001 for all phenotypes except mean gestational week), which was to be expected because the phenotypes that showed the significant differences were associated with the diabetic condition. GDM patients were older, possessed higher BMI than the NGT women and clearly exhibited the clinical characteristics of T2DM, as shown in Table [1](#T1){ref-type="table"}; in comparison to NGT women, GDM patients exhibited higher blood glucose levels and lower beta-cell function when insulin resistance was increased.

We first performed association analyses of the two genetic polymorphisms in GDM and non-GDM subjects to determine whether these polymorphisms were associated with a higher risk of developing GDM, which were previously found to be associated with T2DM (*rs1387153*and *rs10830963*on *MTNR1B)*, with the risk of GDM (Table [2](#T2){ref-type="table"}). The risk allele frequencies of both SNPS are also shown in Table [2](#T2){ref-type="table"}. As a result, both SNPs showed significant associations with GDM in co-dominant, dominant, and recessive models. Co-dominant model exhibited lowest *P*value (0.00008, *Pcor*. = 0.0006, OR (95% CI) = 1.30 (1.06 - 1.66) and 0.00001, *Pcor*. = 0.00008, OR = 1.35 (1.18 - 1.54) for *rs1387153*and *rs10830963*, respectively), and recessive model showed highest *P*value (0.002, OR = 1.42 (1.14 - 1.78) and 0.0001, OR = 1.54 (1.23 - 1.92) respectively for *rs1387153*and *rs10830963*, respectively), while dominant model *P*value was in between the two (0.0007, OR (95% CI) = 1.44 (1.17 - 1.78) and 0.0006, OR = 1.46 (1.18 - 1.81) for *rs1387153*and *rs10830963*, respectively). The risk allele for *rs1387153*was T, and for *rs10830963*, it was G. P-value for Hardy-Weinberg equilibrium of subjects and controls were over 0.05 for both SNPs, indicating that the sample population is in Hardy-Weinberg equilibrium (data not shown). Also, there was a significantly high value of linkage disequilibrium (LD) between the two SNPs (\|*D\'*\| = 0.89). The association results of haplotypes with the 2 SNPs are shown in Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### 

Allele and genotype distributions of *MTNR1B*polymorphisms in GDM and control subjects

  Loci           Genotype   RAF     N (%)   Referent     Co-dominant   Dominant      Recessive                                                                       
  -------------- ---------- ------- ------- ------------ ------------- ------------- ------------ ------------- ------------ ------------- ----------- ------------- -----------
                 CC                         235(25.9%)   313(32.2%)    1                                                                                             
                 CT                         433(47.6%)   455(46.8%)    1.33          0.1          1.3           **0.0008**   1.44          **0.008**   1.42          **0.03**
  *rs1387153*               0.503   0.444                              (1.06-1.66)                (1.14-1.49)                (1.17-1.78)               (1.14-1.78)   
                 TT                         241(26.5%)   204(21.0%)    1.29          **0.001**                                                                       
                                                                       (1.13-1.47)                                                                                   
                                                                                                                                                                     
                 CC                         217(23.9%)   294(30.4%)    1                                                                                             
                 CG                         435(47.9%)   469(48.6%)    1.31          0.2          1.35          **0.0001**   1.46          **0.006**   1.54          **0.001**
  *rs10830963*              0.521   0.453                              (1.04-1.65)                (1.18-1.54)                (1.18-1.81)               (1.23-1.92)   
                 GG                         256(28.2%)   203(21.0%)    1.34          **0.0001**                                                                      
                                                                       (1.18-1.53)                                                                                   

*P*values were corrected for multiple testing by multiplying the number of tests (10 tests, 2 SNPs × 5 tests (2 referent, co-dominant, dominant and recessive models)) (Bonferroni correction). RAF, risk allele frequency.

###### 

Haplotype association analyses with GDM and GDM-related phenotypes

  Haplotype    Frequency   Phenotype                                                     
  ------------ ----------- -------------- ------ ------------- ----------- ------ ------ -----------
  *ht1*(C-C)   0.452       **0.0001**     0.93   **0.0004**    **0.002**   0.19   0.35   **0.01**
  *ht2*(T-G)   0.486       **0.000001**   0.8    **0.00007**   **0.002**   0.08   0.23   **0.002**
  *ht3*(C-G)   0.045       0.25           0.15   0.25          0.8         0.66   0.94   0.17
  *ht4*(T-C)   0.018       **0.008**      0.42   0.94          0.82        0.37   0.44   0.77

Haplotypes were estimated by using PHASE software (Stephens et al.). The association analyses and regression analyses for haplotypes were done by using Haplo. stats (Schaid et al.). *P*values for phenotypes were calculated from multiple linear regression analyses controlling for age, BMI, and number of parities as covariates except BMI phenotypes, which were adjusted for age and number of parities as covariates only. *P*values for phenotypes shown are co-dominant model. \* *P*values for AUC_G, HOMA_B, HOMA_IR, and FPI were calculated after normalizing their data by applying logarithms

###### 

MTNR1B haplotypes\' genotype distribution, means and standard deviations of various phenotypes for GDM

  Phenotype   Loci    C/C                     C/R                    R/R
  ----------- ------- ----------------------- ---------------------- ----------------------
  BMI         *ht1*   518(22.34 ± 3.70)       904(22.34 ± 3.62)      454(22.35 ± 3.59)
              *ht2*   584(22.39 ± 3.64)       896(22.35 ± 3.63)      396(22.28 ± 3.62)
              *ht3*   1719(22.31 ± 3.58)      152(22.72 ± 4.04)      5(23.54 ± 6.94)
              *ht4*   1788(22.36 ± 3.65)      86(22.16 ± 3.21)       2(19.80 ± 1.41)
  AUC_G       *ht1*   449(438.33 ± 74.35)     757(429.75 ± 79.48)    375(420.39 ± 84.28)
              *ht2*   480(420.98 ± 83.23)     753(430.50 ± 78.91)    348(441.20 ± 73.83)
              *ht3*   1446(430.46 ± 80.09)    130(425.51 ± 72.41)    5(405.10 ± 75.33)
              *ht4*   1516(429.95 ± 79.07)    64(431.35 ± 88.89)     1(361.50)
  HOMA_B      *ht1*   509(225.47 ± 126.01)    898(240.16 ± 144.09)   448(254.96 ± 200.10)
              *ht2*   577(251.20 ± 186.38)    889(240.64 ± 143.02)   389(220.51 ± 128.44)
              *ht3*   1700(239.45 ± 157.09)   150(242.64 ± 138.61)   5(239.14 ± 23.78)
              *ht4*   1768(239.99 ± 157.73)   85(232.89 ± 98.82)     2(280.10 ± 66.75)
  HOMA_IR     *ht1*   512(2.66 ± 1.60)        898(2.58 ± 1.45)       450(2.54 ± 1.50)
              *ht2*   579(2.54 ± 1.61)        889(2.59 ± 1.34)       392(2.68 ± 1.68)
              *ht3*   1705(2.59 ± 1.46)       150(2.65 ± 1.95)       5(2.58 ± 1.28)
              *ht4*   1773(2.60 ± 1.52)       85(2.42 ± 1.16)        2(2.00 ± 0.24)
  FPI         *ht1*   512(12.34 ± 6.48)       898(12.09 ± 5.64)      450(12.00 ± 5.71)
              *ht2*   579(11.98 ± 6.12)       889(12.15 ± 5.31)      392(12.35 ± 6.78)
              *ht3*   1705(12.11 ± 5.74)      150(12.45 ± 7.54)      5(12.36 ± 4.49)
              *ht4*   1773(12.17 ± 5.96)      85(11.51 ± 4.61)       2(10.50 ± 0.71)
  FPG         *ht1*   449(86.46 ± 12.66)      757(85.32 ± 11.89)     375(84.49 ± 13.30)
              *ht2*   480(84.49 ± 12.83)      753(85.40 ± 11.82)     348(86.86 ± 13.23)
              *ht3*   1446(85.53 ± 12.66)     130(84.65 ± 10.31)     5(82.20 ± 9.36)
              *ht4*   1516(85.44 ± 12.50)     64(85.64 ± 11.87)      1(80.00)

C/C, C/R, and R/R indicate major homozygote, heterozygote, and minor homozygote, respectively.

FPI, fasting plasma insulin; FPG, fasting plasma glucose

We have also performed regression analysis with various diabetes-related phenotypes, including body mass index (BMI, analyzed controlling for age and the number of parities as covariate), AUC-G, HOMA-B, HOMA-IR, FPI and FPG, with age, BMI, and numbers of parities as covariates (Table [5](#T5){ref-type="table"}). From the analyses, both SNPs showed significant associations for AUC-G, HOMA-B, and FPG with phenotypes among all subjects (Table [5](#T5){ref-type="table"}). The rare alleles of the 2 SNPs were associated with bigger AUC-G, lower HOMA-B, and higher FPG, and these alleles were the risk alleles for GDM (T for *rs1387153*and G for *rs10830963*). To see if a certain SNP was functional, we have performed conditional analyses for GDM and other phenotypes. The results are listed in Table [6](#T6){ref-type="table"}. From the results, *rs10830963*retained its signal, while the significance of *rs1387153*was disappeared, which suggest that *rs1387153*might have shown its signal because of its LD with *rs10830963*, although not clear in GDM-related phenotype analyses.

###### 

Multiple regression analyses of *MTNR1B*polymorphisms with diabetes-related phenotypes among all subjects

  Phenotype   Loci           C/C                    C/R                    R/R                    ***Pacor***.   ***Pbcor***.   ***Pccor***.
  ----------- -------------- ---------------------- ---------------------- ---------------------- -------------- -------------- --------------
  BMI         *rs1387153*    548(22.38 ± 3.65)      888(22.37 ± 3.65)      445(22.24 ± 3.56)      1              1              1
              *rs10830963*   511(22.34 ± 3.60)      904(22.33 ± 3.58)      459(22.37 ± 3.75)      1              1              1
  AUC_G\*     *rs1387153*    454(419.91 ± 81.85)    743(431.31 ± 79.96)    386(439.26 ± 74.28)    **0.0007**     **0.004**      **0.03**
              *rs10830963*   419(421.23 ± 85.41)    763(429.09 ± 78.39)    403(439.14 ± 74.58)    **0.002**      **0.04**       **0.03**
  HOMA_B\*    *rs1387153*    541(252.38 ± 190.86)   882(239.90 ± 143.11)   437(222.90 ± 125.81)   **0.01**       0.29           0.07
              *rs10830963*   505(251.36 ± 191.00)   897(240.78 ± 143.84)   451(223.74 ± 128.37)   **0.03**       0.72           0.04
  HOMA_IR\*   *rs1387153*    543(2.53 ± 1.63)       882(2.59 ± 1.35)       440(2.64 ± 1.62)       1              1              1
              *rs10830963*   507(2.53 ± 1.47)       897(2.57 ± 1.43)       454(2.69 ± 1.65)       1              1              1
  FPI\*       *rs1387153*    543(11.98 ± 6.21)      882(12.15 ± 5.34)      440(12.26 ± 6.56)      1              1              1
              *rs10830963*   507(11.91 ± 5.59)      897(12.07 ± 5.61)      454(12.44 ± 6.64)      1              1              1
  FPG         *rs1387153*    454(84.30 ± 12.71)     743(85.55 ± 12.01)     386(86.58 ± 12.94)     **0.01**       0.07           0.22
              *rs10830963*   419(84.63 ± 13.24)     763(85.13 ± 11.62)     403(86.71 ± 12.99)     **0.04**       0.72           0.07

*P*value was calculated from multiple linear regression analyses controlling for age, BMI, and number of parities as covariates except BMI phenotypes, which was adjusted for age and number of parities as covariates only. *P*a, *P*b, and *P*c designate *P*values for co-dominant, dominant, and recessive models, respectively. *P*values were corrected for multiple testing by multiplying the number of tests (36 tests, 2 SNPs × 3 models × 6 phenotypes) (Bonferroni correction). C/C, C/R, and R/R indicate major homozygote, heterozygote, and minor homozygote, respectively. \* *P*values for AUC_G, HOMA_B, HOMA_IR, and FPI were calculated after normalizing their data by applying logarithms (Data shown are raw values). FPI, fasting plasma insulin; FPG, fasting plasma glucose

###### 

Conditional association analyses of *MTNR1B*genetic variants

  Phenotype   Loci           P         Conditioned P value by   
  ----------- -------------- --------- ------------------------ -----------
  GDM         *rs1387153*    0.00008   \-                       **0.007**
              *rs10830963*   0.00001   0.22                     \-
                                                                
  BMI         *rs1387153*    0.66      \-                       0.59
              *rs10830963*   0.77      0.51                     \-
                                                                
  AUC_G\*     *rs1387153*    0.00002   \-                       0.34
              *rs10830963*   0.00006   0.11                     \-
                                                                
  HOMA_B\*    *rs1387153*    0.0004    \-                       0.25
              *rs10830963*   0.0007    0.07                     \-
                                                                
  HOMA_IR\*   *rs1387153*    0.15      \-                       0.28
              *rs10830963*   0.14      0.12                     \-
                                                                
  FPI\*       *rs1387153*    0.58      \-                       0.89
              *rs10830963*   0.49      0.49                     \-
                                                                
  FPG         *rs1387153*    0.0004    \-                       0.36
              *rs10830963*   0.001     0.85                     \-

Conditional P values were estimated and permutated using the software PLINK (Purcell et al.). \* *P*values for AUC_G, HOMA_B, HOMA_IR, and FPI were calculated after normalizing their data by applying logarithms

Discussion
==========

In previous studies on the *rs1387153*and *rs10830963*, researchers found strong associations between the two SNPs of *MTNR1B*and T2DM, and also with FPG levels, which is an important phenotype for diabetes. A study in European population, which included French and Danish among other nations, showed that *rs1387153*was significantly associated with FPG level (*P*= 1.3 × 10^-7^, adjusted genome-wide *P*= 0.04) and T2DM (OR (95% CI) = 1.15(1.08-1.22), *P*= 6.3 × 10^-5^). Another study in European population found significant associations of *rs10830963*with FPG (*P*= 3.2 × 10^-50^) and T2DM (OR (95% CI) = 1.09(1.05-1.12), *P*= 3.3 × 10^-7^). The Two SNPs were closely related with each other, as evidenced by the linkage disequilibrium test (\|D\'\| = 0.89) in our study. Their haplotype analyses results showed that *ht1*(C/C) and *ht2*(T/G) were mostly tagged by *rs10830963*and *rs1387153*, respectively (\>92%). Therefore, *ht1/ht2*showed similar associations with each SNP, respectively.

Here, we performed the association studies in Korean pregnant women and we found significant associations between the SNPs and GDM, with enough samples for high statistical power. It is well known that T2DM and GDM are closely related diseases, since they exhibit similar characteristics such as glucose intolerance. However, there had yet to be a study that looked into the association between the polymorphisms of *MTNR1B*and GDM, and our study confirmed the relations between the two. Also, we carried out regression analyses between the polymorphisms of *MTNR1B*and various phenotypes including FPG. Although both SNPs showed associations with GDM and FPG, our results suggested that the two genetic variants of *MTNR1B*were stronger risk factors for GDM in Korean population compared to the previous results for T2DM in European population (OR (95% CI) = 1.44 (1.17-1.78) for *rs1387153*in dominant inheritance model and 1.46 (1.18 - 1.81) for *rs10830963*in the present study and OR = 1.15 (1.08-1.22) for *rs1387153*and OR = 1.09 (1.05-1.12) for *rs10830963*in the two previous studies). We suspect that the genetic differences between GDM and T2DM and the population difference between Europeans and Asians could have contributed to this result. Previously, there have been a few cases where a gene associated with T2DM was not associated with GDM at all \[[@B20]\], or showed different effect sizes \[[@B21],[@B22]\], and our results suggest that *MTNR1B*affects T2DM and GDM in varying degrees as well.

Moreover, our results suggest that the two polymorphisms investigated are associated with beta-cell function (Table [5](#T5){ref-type="table"}). Association between beta-cell function and *MTNR1B*was previously reported \[[@B18],[@B23]\], which shows that we were able to replicate the result in Korean population, strengthening the notion that *MTNR1B*polymorphisms are related with impaired beta-cell function. Recently, several groups of scientists have studied the association between the gene variants of *MTNR1B*and glucose tolerances. *rs10830963*was found to be associated with FPG and decreased beta-cell function in a group of obese children, which is consistent with our finding \[[@B24]\]. Three independent studies of the *MTNR1B*genetic variants in Han Chinese subjects also found significant associations for increased FPG, impaired beta-cell function, glycated hemoglobin, and T2DM \[[@B18],[@B25],[@B26]\]. Furthermore, a study with European populations also found significant associations between variations of *MTNR1B*with BMI and FPG, but not with maturity-onset diabetes of the young (MODY) or T2DM \[[@B27]\]. Although some of their results do not agree with each other in the association with T2DM, these findings firmly back up the association between the SNPs in our study and FPG or impaired beta-cell function. On the other hand, we could not find any significant associations between insulin resistance (HOMA-IR) and the two genetic variants. Since our results are backed with high statistical power, this leads us to conclude that two genetic variants of *MTNR1B*may be associated with the disease by affecting glucose metabolism through impaired insulin secretion, as previously suggested by other studies with *KCNQ1*genetic variants \[[@B8],[@B18],[@B28]\].

In addition, further conditional analyses results suggested that *rs10830963*might be more likely functional in case/control analysis, although not clear in GDM-related phenotype analyses.

Although our results showed the significant associations with GDM and several diabetic characteristics, there are a couple of limitations. First, our study only concentrated on pregnant women among Korean population, so we cannot conclude that the *MTNR1B*gene variants are associated with FPG or impaired beta-cell function in all Korean population. Also, even though our study strongly suggests that the SNPs may also be associated with T2DM in Korean population, this is not confirmed yet. Any further studies on these two genetic variants in Korean population should concentrate on these parts.

Conclusions
===========

The present study showed that two *MTNR1B*polymorphisms were associated with increased risk for GDM in Korean female population. Two polymorphisms *rs1387153*and *rs10830963*also showed significant associations with FPG and beta-cell function, but not with insulin resistance. Further conditional analyses results suggested that *rs10830963*might be more likely functional in case/control analysis, although not clear in GDM-related phenotype analyses. The effective sizes found between the two polymorphisms and FPG was stronger compared to previous studies, which is possibly due to the genetic difference between European and Korean populations, or the difference between GDM and T2DM. Based on the current results, we suspect that these two polymorphisms will have significant associations with increased risk of GDM in other populations as well. Also, our discovery would be helpful for understanding of genetic etiology of GDM as well.
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